Jpmorgan Chase & CO Prothena Corp Public LTD CO Transaction History

Jpmorgan Chase & CO

  • $1.23 Trillion
  • Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Jpmorgan Chase & CO holds 387,350 shares of PRTA stock, worth $5.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
387,350
Previous 199,986 93.69%
Holding current value
$5.55 Million
Previous $3.35 Million 60.36%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
BUY
$11.95 - $18.35 $2.24 Million - $3.44 Million
187,364 Added 93.69%
387,350 $5.36 Million
Q3 2024

Dec 26, 2024
SELL
$16.73 - $24.79 $1.61 Million - $2.38 Million
-95,979 Reduced 32.43%
199,986 $3.35 Million
Q3 2024

Nov 08, 2024
SELL
$16.73 - $24.79 $1.61 Million - $2.38 Million
-95,979 Reduced 32.43%
199,986 $3.35 Million
Q2 2024

Dec 26, 2024
BUY
$19.54 - $26.15 $1.88 Million - $2.51 Million
95,979 Added 47.99%
295,965 $6.11 Million
Q2 2024

Aug 12, 2024
SELL
$19.54 - $26.15 $41,542 - $55,594
-2,126 Reduced 0.71%
295,965 $6.11 Million
Q1 2024

Dec 26, 2024
BUY
$24.75 - $40.66 $2.43 Million - $3.99 Million
98,105 Added 49.06%
298,091 $7.38 Million
Q1 2024

May 10, 2024
SELL
$24.75 - $40.66 $1.49 Million - $2.46 Million
-60,387 Reduced 16.85%
298,091 $7.38 Million
Q4 2023

Dec 26, 2024
BUY
$32.31 - $52.32 $5.12 Million - $8.29 Million
158,492 Added 79.25%
358,478 $13 Million
Q4 2023

Feb 12, 2024
SELL
$32.31 - $52.32 $1.41 Million - $2.28 Million
-43,553 Reduced 10.83%
358,478 $13 Million
Q3 2023

Nov 14, 2023
SELL
$47.3 - $70.6 $569,208 - $849,600
-12,034 Reduced 2.91%
402,031 $19.4 Million
Q2 2023

Aug 11, 2023
BUY
$48.26 - $78.59 $4.17 Million - $6.79 Million
86,347 Added 26.35%
414,065 $28.3 Million
Q1 2023

May 18, 2023
BUY
$46.97 - $58.27 $2.31 Million - $2.87 Million
49,259 Added 17.69%
327,718 $15.9 Million
Q1 2023

May 11, 2023
SELL
$46.97 - $58.27 $5.92 Million - $7.35 Million
-126,092 Reduced 31.17%
278,459 $13.5 Million
Q4 2022

Feb 13, 2023
BUY
$52.05 - $65.0 $6.37 Million - $7.95 Million
122,369 Added 43.37%
404,551 $24.4 Million
Q3 2022

Nov 14, 2022
SELL
$25.16 - $60.63 $110,628 - $266,590
-4,397 Reduced 1.53%
282,182 $17.1 Million
Q2 2022

Aug 11, 2022
BUY
$22.73 - $39.98 $782,798 - $1.38 Million
34,439 Added 13.66%
286,579 $7.78 Million
Q1 2022

May 11, 2022
BUY
$30.27 - $49.22 $1.11 Million - $1.81 Million
36,798 Added 17.09%
252,140 $9.22 Million
Q4 2021

Feb 10, 2022
BUY
$42.11 - $73.26 $8.47 Million - $14.7 Million
201,056 Added 1407.36%
215,342 $10.6 Million
Q3 2021

Nov 12, 2021
BUY
$48.2 - $78.89 $688,585 - $1.13 Million
14,286 New
14,286 $1.02 Million

Others Institutions Holding PRTA

# of Institutions
198
Shares Held
44.5M
Call Options Held
601K
Put Options Held
259K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $672M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email